HSP90AA1 and systemic lupus erythematosus: Recent data from animal models of experimentally induced autoimmune encephalomyelitis [5], rheumatoid arthritis [6], [7] and systemic lupus erythematosus [8], [9] indicate that pharmacological inhibition of Hsp90 may represent a novel potential treatment of autoimmune disorders.